

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 42, 48, and 49 are amended, claims 60 and 70 are canceled, and new claims 71-73 are added.

42. (Currently Amended) A chimeric anti-human CD23 antibody ~~which~~ wherein the light chain variable ~~light~~ domain ~~comprises~~ consists of the variable domain polypeptide encoded by SEQ ID NO: 1, the heavy chain variable ~~heavy~~ domain ~~comprises~~ consists of the variable domain polypeptide encoded by SEQ ID NO: 2, and ~~comprising~~ the constant region is a human constant region selected from the group consisting of human gamma -1 and human gamma -3 constant regions.

43. The anti-human CD23 antibody of claim 42 wherein the human constant region is a human gamma -1 constant region.

44. The anti-human CD23 antibody of claim 42 wherein the human constant region is a human gamma -3 constant region

45. A composition containing an anti-human CD23 antibody according to claim 42 and a pharmaceutically acceptable carrier.

46. A composition containing an anti-human CD23 antibody according to claim 43 and a pharmaceutically acceptable carrier.

47. A composition containing an anti-human CD23 antibody according to claim 44 and a pharmaceutically acceptable carrier.

48. (Currently Amended) A chimeric anti-human CD23 antibody wherein the light chain variable ~~light~~ domain ~~comprises~~ consists of the variable domain polypeptide encoded by SEQ ID NO: 3, ~~and~~ the heavy chain variable ~~heavy~~ domain ~~comprises~~ consists of the variable domain polypeptide encoded by nucleotides 58-411 of SEQ ID NO: 4, and the constant region is a human constant region selected from the group consisting of a human gamma -1 constant region and a human gamma -3 constant region.

49. (Currently Amended) A chimeric anti-human CD23 antibody wherein the light chain variable ~~light~~ domain ~~comprises~~ consists of the variable domain polypeptide encoded by SEQ ID NO: 3 and the heavy chain variable ~~heavy~~ domain ~~comprises~~ consists of the variable domain polypeptide encoded by SEQ ID NO: 4 with the exception that the asparagine codon ~~at position 75~~ encoded by nucleotides 289-291 of SEQ ID NO: 4 is replaced with a lysine codon.

50. The anti-human CD23 antibody according to claim 48 which comprises a human gamma -1 constant region.

51. The anti-human CD23 antibody according to claim 48 which comprises a human gamma -3 constant region.

52. The anti-human CD23 antibody according to claim 49 which comprises gamma -1 constant region.

53. The anti-human CD23 antibody according to claim 49 which comprises a human gamma -3 constant region.

54. A composition comprising an anti-human CD23 antibody according to claim 48 and a pharmaceutically acceptable carrier.

55. A composition comprising an anti-human CD23 antibody according to claim 49 and a pharmaceutically acceptable carrier.

56. A composition comprising an anti-human CD23 antibody according to claim 50 and a pharmaceutically acceptable carrier.

57. A composition comprising an anti-human CD23 antibody according to claim 51 and a pharmaceutically acceptable carrier.

58. A composition comprising an anti-human CD23 antibody according to claim 52 and a pharmaceutically acceptable carrier.

59. A composition comprising an anti-human CD23 antibody according to claim 53 and a pharmaceutically acceptable carrier.

60. (Canceled).

61. The composition of claim 45, which composition is a pharmaceutical composition.

62. The composition of claim 46, which composition is a pharmaceutical composition.

63. The composition of claim 47, which composition is a pharmaceutical composition.

64. The composition of claim 54, which composition is a pharmaceutical composition.

65. The composition of claim 55, which composition is a pharmaceutical composition.

66. The composition of claim 56, which composition is a pharmaceutical composition.

67. The composition of claim 57, which composition is a pharmaceutical composition.

68. The composition of claim 58, which composition is a pharmaceutical composition.

69. The composition of claim 59, which composition is a pharmaceutical composition.

70. (canceled).

71. (new) The chimeric anti-human CD23 antibody of claim 42, wherein the light chain variable domain consists of the polypeptide encoded by nucleotides 58-390 of SEQ ID NO: 1, and the heavy chain variable domain consists of the polypeptide encoded by nucleotides 58-423 of SEQ ID NO: 2.

72. (new) The chimeric anti-human CD23 antibody of claim 48, wherein the light chain variable domain consists of the polypeptide encoded by nucleotides 67-387 of SEQ ID NO: 3, and the heavy chain variable domain consists of the polypeptide encoded by nucleotides 58-411 of SEQ ID NO: 4.

73. (new) The chimeric anti-human CD23 antibody of claim 49, wherein the light chain variable domain consists of the polypeptide encoded by nucleotides 67-387 of SEQ ID NO: 3, and the heavy chain variable domain consists of the polypeptide encoded by nucleotides 58-411 of SEQ ID NO: 4 with the exception that the asparagine codon encoded by nucleotides 289-291 of SEQ ID NO: 4 is replaced with a lysine codon.